• Viking Therapeutics is approaching a Q3 data readout from its VK2735 obesity drug maintenance trial.
• The company also plans to start a pivotal late stage study of an oral VK2735 formulation later this year.
• These two clinical milestones are new developments for Viking Therapeutics and may influence how investors view NasdaqCM:VKTX in the obesity drug space.

Viking Therapeutics, trading on NasdaqCM:VKTX, is drawing attention as it works toward these clinical catalysts while its share price stands at $29.33. The stock is up 8.6% over the past year and has delivered a very large gain over the past 5 years, although it is down 17.2% year to date. This mix of long term gains and recent pressure sets the backdrop for how the next data points could be received.

For investors tracking obesity drug developers, the upcoming VK2735 maintenance data and the planned pivotal oral study introduce fresh information that has not yet been reflected in earlier coverage of the company. How these studies progress, including safety and efficacy outcomes, could play a role in how the market compares Viking Therapeutics with other weight loss drug developers.

Stay updated on the most important news stories for Viking Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Viking Therapeutics.

Quick Assessment

• ✅ Price vs Analyst Target: At US$29.33, VKTX trades about 68% below the US$92.58 analyst consensus target.
• ❌ Simply Wall St Valuation: Shares are described as trading 282.6% above the platform's estimated fair value.
• ❌ Recent Momentum: The stock is down 7.7% over the last 30 days heading into these trial milestones.

There is only one way to know the right time to buy, sell or hold Viking Therapeutics. Head to Simply Wall St's company report for the latest analysis of Viking Therapeutics's fair value.

Key Considerations

• 📊 The VK2735 maintenance data and pivotal oral study could influence how the market weighs VKTX against other obesity drug developers.
• 📊 Watch the timing and content of trial readouts, cash burn relative to zero revenue, and any updates to analyst targets after new data.
• ⚠️ With no meaningful revenue and ongoing losses, any disappointing clinical outcome could matter more given the current premium to estimated fair value.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Viking Therapeutics analysis. Alternatively, you can check out the community page for Viking Therapeutics to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.